glp-1 types receptor agonists GLP-1 Agonists - What is
Description
The primary safety risks come from unverified suppliers offering untested products, incorrect concentrations, or contaminated peptides
We ensure that you are fully informed about the potential side effects and committed to adhering to the prescribed treatment plan
doi:10.2337/dc11-s229 76 GallwitzB
It dramatically increases the risk of severe nausea, vomiting, and other GI side effects without improving efficacy
The Physiology of Glucagon-Like Peptide 1
Gastrointestinal symptoms occur frequently during initial treatment phases: Nausea : Affects many patients during dose escalation periods
